Danoprevir Sodium/Ritonavir Drug Due Diligence Report 2026

This Danoprevir Sodium/Ritonavir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Danoprevir Sodium/Ritonavir can convert its Small molecule drug profile and HIV-1 pol x NS3/NS4A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Danoprevir Sodium/Ritonavir (query alias: Danoprevir Sodium/Ritonavir)
Modality / target	Small molecule drug; HIV-1 pol x NS3/NS4A; HIV-1 pol inhibitors, NS3/NS4A inhibitors
Highest global status	Phase 3
Originator	F. Hoffmann-La Roche Ltd.
Active developers	F. Hoffmann-La Roche Ltd.

The MCP disease footprint includes Hepatitis C. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07709520	Phase 2	Recruiting	80	HBsAg decline from baseline at D168
CTR20262451	Phase 2	进行中（尚未招募）	80	Not disclosed
CTR20262450	Phase 2	进行中（尚未招募）	80	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: HBsAg = -87.12 %

Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: -; T1/2 = 3.88 - 14.3 Hour

A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1

Phase 3; n=141; evaluation: not stated. Reported fields: Proportion of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) = 136 Participants ; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Danoprevir Sodium/Ritonavir addresses Hepatitis C. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2016-02-26	福建广生堂药业股份有限公司与药明康德签订了“治疗乙肝新药 GST-HG131 的研发”的《合作开发合同书》	Preclinical	US$4.9M stated total
2013-04-15	Roche and Ascletis enter collaboration to advance treatment options for Chinese patients with Hepatitis C	Phase 2	Financial terms not disclosed
2004-12-31	Array BioPharma Inc.and InterMune entered into a drug discovery collaboration agreement to create small molecule therapeutics targeting HCV with Array.	Discovery	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO